skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane

Review

(2914) Views  (1116) Full article downloads

Authors: Iain RJ Macpherson, Colin Lindsay, Peter Canney

Published Date October 2010 Volume 2010:2 Pages 59 - 70
DOI: http://dx.doi.org/10.2147/BCTT.S11835

Iain RJ Macpherson1,3, Colin Lindsay2, Peter Canney3

1Centre for Oncology and Applied Pharmacology, University of Glasgow, Glasgow, Scotland, UK; 2Beatson Institute for Cancer Research, Glasgow, Scotland, UK; 3Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK

Abstract: Adjuvant hormonal therapy significantly reduces the risk of recurrence and death following surgery for estrogen receptor (ER)-positive early breast cancer. Previously, the gold standard hormonal therapy was tamoxifen, a selective modulator of the ER. However, large clinical trials conducted over the past decade have defined the efficacy of an alternative class of hormonal agent, namely the third-generation aromatase inhibitors (AIs): exemestane, letrozole, and anastrozole. On the basis of the pivotal International Exemestane Study (IES), exemestane, a steroidal third-generation AI, was licensed for the adjuvant treatment of postmenopausal women with ER-positive early breast cancer following 2–3 years of tamoxifen to complete a total of 5 years of adjuvant hormonal therapy. Here, we consider recent data to emerge primarily from the IES and Tamoxifen Exemestane Adjuvant Multicenter trials and consider their implications for the role of exemestane in the adjuvant treatment of breast cancer.

Keywords: breast cancer, exemestane, aromatase, tamoxifen








Readers of this article also read:

New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin
HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites
Effect of HIV infection on time to recovery from an acute manic episode
HER2-positive male breast cancer: an update
Current and emerging treatment strategies for breast cancer-induced bone loss
Lapatinib: new opportunities for management of breast cancer
Role of trastuzumab in the management of HER2-positive metastatic breast cancer
Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
The use of preexposure treatments for HIV prophylaxis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University